222 related articles for article (PubMed ID: 25599619)
1. Clinical trials. Rituximab for maintenance of remission in AAV.
Tanna A; Pusey C
Nat Rev Nephrol; 2015 Mar; 11(3):131-2. PubMed ID: 25599619
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
3. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
4. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
5. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
7. Rituximab or azathioprine maintenance in ANCA-associated vasculitis.
Chouchana L; Beaune P; Loriot MA
N Engl J Med; 2015 Jan; 372(4):386. PubMed ID: 25607436
[No Abstract] [Full Text] [Related]
8. Rituximab or azathioprine maintenance in ANCA-associated vasculitis.
Vandergheynst F
N Engl J Med; 2015 Jan; 372(4):385-6. PubMed ID: 25607435
[No Abstract] [Full Text] [Related]
9. Rituximab or azathioprine maintenance in ANCA-associated vasculitis.
Hebert LA; Alvarado A; Rovin B
N Engl J Med; 2015 Jan; 372(4):385. PubMed ID: 25607434
[No Abstract] [Full Text] [Related]
10. Rituximab or azathioprine maintenance in ANCA-associated vasculitis.
Pagnoux C; Guillevin L; ;
N Engl J Med; 2015 Jan; 372(4):386-7. PubMed ID: 25607433
[No Abstract] [Full Text] [Related]
11. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
Santana AN; Woronik V; Halpern AS; Barbas CS
J Bras Pneumol; 2011; 37(6):809-16. PubMed ID: 22241040
[TBL] [Abstract][Full Text] [Related]
12. Extending the indications for rituximab in ANCA-associated vasculitis.
Jayne D
N Engl J Med; 2014 Nov; 371(19):1839-40. PubMed ID: 25372093
[No Abstract] [Full Text] [Related]
13. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
15. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
Jayne D
Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
[No Abstract] [Full Text] [Related]
16. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA;
Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796
[TBL] [Abstract][Full Text] [Related]
17. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U
Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for ANCA-associated vasculitides.
Guillevin L
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]